PMID: 11921124Mar 29, 2002Paper

Tardive dyskinesia model in the common marmoset

Movement Disorders : Official Journal of the Movement Disorder Society
Rebecka KlintenbergP Andren

Abstract

Thirteen adult common marmosets (Callithrix jacchus) were given once-monthly injections of haloperidol decanoate (5-15 mg/kg i.m.) for one year. Thereafter, drug-free and treatment periods alternated at 3-month intervals. After 2.5 to 14 months, 12 monkeys showed symptoms of tardive dyskinesia (TD), such as periocular and perioral twitchings, tongue protrusions, masticatory movements, and choreic movements in arms and legs. When TD symptoms were evident, the periodic treatment was interrupted and symptoms persisted for at least 5 months after the last haloperidol dose, worsened by injection of the anticholinergic drug biperiden. An injection of nondepot haloperidol (0.12 or 0.25 mg/kg) produced a reduction of TD symptoms. At the end of the study, nondepot haloperidol was injected once a week at two doses (0.12 and 0.25 mg/kg i.m.). A syndrome of excitation with peculiar behavior, interpreted as acute dystonia, was precipitated in all animals. The animals showed sustained retrocollis, climbing upside down, biting the perch, repetitive turnings, and frequent backward movements. The dystonic movements lasted approximately 6 hours and were reduced but not completely extinguished by biperiden (0.1 mg/kg). The TD syndrome registered ...Continue Reading

References

Jun 1, 1977·Brain : a Journal of Neurology·B S MeldrumC D Marsden
Aug 1, 1977·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·P BédardL Larochelle
Aug 16, 1977·Psychopharmacology·B WeissG Lusink
Nov 24, 1976·Psychopharmacology·L M Gunne, S Bárány
Jul 1, 1977·The American Journal of Psychiatry·C A TammingaJ M Davis
Sep 1, 1990·The American Journal of Psychiatry·R YassaG Schwartz
Oct 1, 1986·Pharmacology, Biochemistry, and Behavior·L M GunneP Johansson
Aug 1, 1988·Journal of Clinical Psychopharmacology·J LiebermanJ Kane
Jan 1, 1973·The American Journal of Psychiatry·H L Klawans
Jan 1, 1981·Psychopharmacology·R D Porsolt, M Jalfre
Feb 1, 1984·Journal of Clinical Psychopharmacology·M Branchey, L Branchey
Jan 1, 1980·Psychopharmacology·D E CaseyE Christensson
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·P J BédardL Larochelle
Jan 4, 1998·Pharmacology, Biochemistry, and Behavior·T FukuokaM Matsuo

❮ Previous
Next ❯

Citations

Jan 9, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Joseph H Friedman
Mar 13, 2012·Behavioral and Brain Functions : BBF·Pierre J BlanchetDaniel Lévesque
Nov 22, 2008·Progress in Neurobiology·Dominique GuehlPierre Burbaud
Jul 22, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Peter Jenner
Mar 21, 2017·Frontiers in Neurology·Gaetana ChillemiAngelo Quartarone
Mar 18, 2005·Journal of Neuroscience Research·A IwanamiH Okano
Jul 29, 2017·Expert Review of Neurotherapeutics·Haitham SalemAntonio L Teixeira
Apr 16, 2004·The Veterinary Record·D Espinosa-AvilésP Varela

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here